Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Paul G Richardson,Craig C Hofmeister,Cara A Rosenbaum,Myo Htut,David H Vesole,Jesus Berdeja,Michaela Liedtke,Ajai Chari,Stephen D Smith,Daniel Lebovic,Deborah Berg,Eileen Liao,Neeraj Gupta,Alessandra Di Bacco,Jose Estevam,Ai-Min Hui,Rachid Baz

doi:10.1182/blood.v122.21.535.535

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Paul G Richardson, Craig C Hofmeister + Show 15 more

https://doi.org/10.1182/blood.v122.21.535.535

Copy DOI

Journal: Blood	Publication Date: Nov 15, 2013
Citations: 19

Affiliation: Dana-Farber Cancer Institute, The Ohio State University, University of Chicago, City Of Hope National Medical Center, Hackensack University Medical Center, Stanford University, Icahn School of Medicine at Mount Sinai, Fred Hutch Cancer Center, University of Michigan–Ann Arbor, Millennium Engineering and Integration (United States), Moffitt Cancer Center

#Takeda Oncology Company #Advisory Committees + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.